CG Oncology (CGON) announced that it has completed enrollment in its Phase 3, randomized, open-label PIVOT-006 study comparing adjuvant intravesical cretostimogene grenadenorepvec versus surveillance following bladder tumor removal in patients with intermediate-risk non-muscle invasive bladder cancer, IR NMIBC.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGON:
- CG Oncology initiated with an Overweight at Piper Sandler
- CG Oncology’s Strategic Advancements and Promising Data Reinforce Buy Rating
- CG Oncology price target lowered to $62 from $63 at BofA
- CG Oncology’s Q2 2025: Clinical Advances and Legal Wins
- Buy Rating for CG Oncology, Inc. Driven by Promising Clinical Data and Strategic Advancements